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Introduction
The NOD-like receptor, pyrin domain containing protein 3
(NLRP3) is a pattern recognition receptor (PRR) activated by
wide-ranging stimuli to mediate the release of pro-inflammato-
ry cytokines interleukin (IL)-1b and IL-18. Chronic activation of
NLRP3 is implicated in a surprisingly wide variety of non-com-
municable diseases,[1] including metabolic dysregulation, T-cell
mediated or organ specific autoimmune diseases, systemic au-
toimmune diseases and inflammatory reactions in skin, joints,
muscle, heart and brain.[2] NLRP3 acts as an intracellular signal-
ing molecule sensing pathogen, environmental and host-de-
rived stress.[1] This contrasts with other PRRs which are primari-
ly responsible for microbial recognition.[3] Several proposed
mechanisms of NLRP3 activation have been thoroughly re-
viewed elsewhere, all of which involve a two-signal process.[4]
The first signal, known as priming, up-regulates the expression
of inactive cytokines and inflammasome components. Priming
is followed by an activation step, this involves oligomerisation
of NLRP3 and recruitment of adapter proteins and pro-cas-
pase-1 to form the NLRP3 inflammasome. The multi-protein
complex serves as a scaffold for the activation of caspase-1, a
proteolytic enzyme which cleaves inactive pro-inflammatory
cytokines, pro-IL-1b and pro-IL-18, into their active secreted
forms IL-1b and IL-18. These cytokines promote the release of
pro-inflammatory mediators and amplify the inflammatory re-
sponse.[5] Additionally, mature caspase-1 mediates a form of in-
flammatory cell death known as pyroptosis.[2b]
Investigation into the role of inflammation in type 2 diabetes
(T2D) has attracted significant attention in recent years, illumi-
nating the complexity of the metabolic disorder.[6] High-fat,
high-calorie diets cause excessive glucose and free fatty acids
(FFA) to stress pancreatic islets and adipose tissue, leading to
immune cell recruitment and inflammation.[7] Obesity instigates
T2D pathogenesis by up-regulating the expression of pro-in-
flammatory “M1” macrophages in adipose tissue which infil-
trate the pancreas, promote insulin resistance and increase
NLRP3 expression.[8] NLRP3 is primed, within both pancreatic
b-cells and macrophages, by FFA or lipopolysaccharide (LPS)
and subsequently activated by a range of danger signals prev-
alent amongst obese individuals.[9] These signals include glu-
cose, FFA, ceramide, uric acid, cholesterol crystals and pancre-
atic amyloid deposits formed by islet amyloid polypeptide.[4]
NLRP3 inflammasome activation and the consequent produc-
tion of caspase-1, IL-18 and IL-1b promotes pancreatic islet in-
flammation, impairs insulin secretion and initiates pyroptotic
and apoptotic pancreatic b-cell death.[10] Moreover, for diabet-
ics the implications of aberrant NLRP3 activation extends
beyond pancreatic damage and impaired glycaemic control,
with complications such as nephropathy, coronary atheroscle-
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rosis, neuroinflammation and wound healing all closely associ-
ated with NLRP3 activation.[4b,11]
The validity of targeting IL-1b in T2D is supported by clinical
evidence and animal models.[12] NLRP3 knockout mice fed a
high-fat diet showed improved glucose tolerance and insulin
sensitivity.[8c,13] In the clinic, several biotherapeutics have suc-
cessfully targeted IL-1 pathways. For example a clinical study
of subcutaneously injected anakinra, a recombinant IL-1 recep-
tor antagonist improved glycaemia, b-cell secretory function
and decreased markers of systemic inflammation.[14] However
this approach indiscriminately blocks IL-1 signalling, rendering
subjects immunocompromised.[4b] In contrast NLRP3 inhibition
is much more specific, leaving other IL-1 pathways fully re-
sponsive. Potent and selective NLRP3 inhibitors are required to
fully understand the therapeutic potential of blocking only
NLRP3 mediated IL-1b release in T2D.
A 2015 review by Baldwin et al. details many of the known
NLRP3 inhibitors.[15] Thus far most NLRP3 inhibitors have po-
tency in the micromolar range, are often unselective and/or
contain reactive functional groups including Michael acceptors,
thiol traps and/or epoxides. One exception is the sulfonylurea
MCC950 (Figure 1), also known as CRID3, the most potent
(IC50=8 nm), selective and well-characterised NLRP3 inhibitor
to date.[16] Another previously identified NLRP3 inhibitor of the
sulfonylurea class, albeit with activity only at micromolar con-
centrations, is glyburide (Figure 1) and its sulfonamide precur-
sor 16673-24-0.[17]
Sulfonylurea drugs, such as glyburide (2), are used thera-
peutically in the treatment of T2D, triggering insulin secretion
from pancreatic b-cells. The insulinotropic properties of sulfo-
nylureas are due to binding with sulfonylurea receptors (SUR)
in the pancreatic b-cell membrane. This interaction closes ATP-
dependent potassium channels (KATP) causing membrane depo-
larisation and Ca2+ influx through voltage-gated calcium chan-
nels.[18] High intracellular Ca2+ concentrations then stimulate
the exocytosis of insulin-containing secretory granules ulti-
mately reducing glycaemia.[19] Unfortunately as T2D progresses,
sulfonylureas become decreasingly effective, due to progres-
sive b-cell death.[10,20] A means of stimulating insulin secretion
while curtailing b-cell death could be a promising approach to
long-term T2D treatment.
Sulfonylurea T2D drugs are loosely classified as first (Gen1)
or second generation (Gen2) therapeutics, the primary differ-
ence being the increased affinity of Gen2 sulfonylurea for the
SUR, attributed to the additional p-b-arylcarboxamidoethyl
group (see Figure 2).[21] The Gen2 sulfonylurea glyburide is par-
ticularly interesting, as it has a weak dual mode of action. Gly-
buride can act as an insulin secretagogue, via closure of b-cell
KATP channels, and as a weak anti-inflammatory via inhibition of
NLRP3 (IC50=20 mm). The independence of these two path-
ways was demonstrated by Lamkanfi et al. , where it was con-
cluded NLRP3-mediated IL-1b production was not dependent
on KATP channels.
[17c] However improvements to the NLRP3 in-
hibitory-potency of sulfonylurea drugs are necessary to im-
prove the likelihood of in vivo efficacy and avoid potential for
high dose-associated toxicity.[22] We report herein the first
potent dual action NLRP3 inhibitors, leveraging known struc-
ture–activity relationships (SAR) of insulin-secretory sulfonylur-
ea drugs and NLRP3-inhibitory potency of MCC950.
Results and Discussion
Known sulfonylurea drugs were tested for NLRP3-inhibition to
establish initial SAR. We then synthesised nine molecular hy-
brids of these sulfonylureas incorporating the s-hexahydroinda-
cene of MCC950 and found all exhibited potent NLRP3-inhibi-
tory activity. The hybrids were tested for their insulin secretory
properties and compared with glyburide (2), from this work six
novel dual action anti-inflammatory sulfonylureas were identi-
fied.
NLRP3-inhibitory activity of known sulfonylureas
Eleven known T2D sulfonylurea drugs, their related sulfona-
mide precursors and the experimental antineoplastic agent su-
lofenur (3) were screened as NLRP3 inhibitors (Table 1).[23] The
NLRP3-inhibition of each compound was tested by measuring
IL-1b secretion from murine bone marrow-derived macrophag-
es (BMDM). BMDM were primed with lipopolysaccharide (LPS),
treated with the test compound (to a maximum concentration
of 200 mm) and finally stimulated with ATP. The half-maximal
inhibitory concentration (IC50) was determined for each com-
pound and compared with the previously reported NLRP3 in-
hibitor MCC950 (Table 1, left column).[16d] As expected MCC950
(IC50=8 nm) was a significantly more potent NLRP3
inhibitor than tested sulfonylurea drugs. Glyburide
(IC50=20 mm) was the most potent NLRP3 inhibitor
of the sulfonylurea drugs tested, and is similar to the
experimental compound 3 (IC50=30 mm). Glimepiride
(IC50=52 mm), gliquidone (IC50=100 mm) and glisoxe-
pide (IC50=156 mm) had modest potency while re-
maining sulfonylureas failed to inhibit 50% of NLRP3
activity at 200 mm. The data generated for glyburide
(2) glipizide (10) and sulofenur (3) reconciles withFigure 1. NLRP3-inhibitory sulfonylureas.
Figure 2. General structures of T2D sulfonylurea drugs.
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Table 1. NLRP3-inhibitory activity of sulfonylureas and precursor sulfonamides.
Compound Structure IC50
(pIC50SD)[#]
Compound Structure IC50
(pIC50SD)[#]
MCC950
(1)
7.5 nm[a] 1a >200 mm[e]
Glyburide
(2)
20 mm[b]
(4.70.1)
16673-24-0
(2a)
>200 mm[d]
Sulofenur
(3)
30 mm[c]
(4.50.1) 3a >200 mm
[e]
Glimepiride
(4)
52 mm[d]
(4.30.1) 4a >200 mm
[c]
Gliquidone
(5)
100 mm[d]
(4.00.1) 5a >200 mm
[c]
Glisoxepide
(6)
156 mm[d]
(3.80.2) 6a >200 mm
[c]
Acetohexamide
(7)
>200 mm[d] 7a
169 mm
(3.80.1)[e]
Carbutamide
(8)
>200 mm[d] 8a >200 mm[e]
Chlorpropamide
(9)
>200 mm[c] 9a >200 mm[e]
Glipizide
(10)
>200 mm[b] 10a >200 mm[e]
Gliclazide
(11)
>200 mm[c]
Tolazamide
(12)
>200 mm[d]
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prior reports, with the remaining sulfonlyureas having not
been previously tested for NLRP3 inhibition.[16b,17c]
The sulfonamides, corresponding to the screened sulfonylur-
eas, were likewise screened for NLRP3-inhibitory activity
(Table 1, right column). The NLRP3 IC50’s of tested sulfonamides
were above 200 mm, with the exception of 7a (IC50=159 mm).
Even sulfonamide 16673-34-0 (2a), the glyburide precursor,
previously reported as an inhibitor of NLRP3 was not active at
200 mm in our hands, all controls were in line with expected
values.[17a] In all but one instance, the sulfonamide was a less
potent NLRP3 inhibitor than the corresponding sulfonylurea.
This implies the sulfonylurea motif and/or the s-hexahydroin-
dacene R1 group are contributing to NLRP3 inhibition. It was
also noted that compound 3, the only compound, other than
MCC950, to have an aromatic R1 group, was more potent than
all marketed sulfonylureas.
Synthesis and NLRP3-inhibitory activity of MCC950–-
sulfonylurea hybrids
A medicinal chemistry strategy was devised to improve the
NLRP3-inhibitory activity of known sulfonylurea compounds
whilst maintaining insulinotropic properties. We focused on re-
placing the R1 moiety of the aforementioned sulfonylurea set
with the s-hexahydroindacene R1 moiety of MCC950. The
MCC950–sulfonylurea hybrids were prepared from the corre-
sponding sulfonamide and hexahydro-s-indacen-4-amine via a
two-step reaction (Scheme 1). Sulfonamides were treated with
sodium hydride to form the corresponding sodium salts. Mean-
while the aniline was treated with di-tert-butyl dicarbonate
(Boc2O) and N,N-dimethylpyridin-4-amine (DMAP) in tetrahy-
drofuran (THF) to form the isocyanate in situ.[24] The isocyanate
and sodium salt mixtures were combined and stirred at room
temperature until judged complete by LC–MS. All but three of
the sulfonamides were commercially obtained. Sulfonamides
5a and 10a were synthesised via the cleavage of 5 and 10 re-
spectively with phthalic anhydride and DMAP.[25] Sulfonamide
6a was prepared from an acid chloride and primary amine (de-
tailed in experimental section).
Comparing the MCC950–sulfonylurea hybrids (Table 2) to
the parent sulfonylurea (Table 1) a striking increase in potency
was observed. This series of NLRP3 inhibitors ranks amongst
the most potent published to date, superseded by only
MCC950 and the sesquiterpene lactone arglabin.[16,26] Interest-
ingly the hybrids based on Gen1 sulfonylureas are generally
more potent NLRP3 inhibitors than the higher molecular
weight Gen2 sulfonylurea hybrids. The notable exception
being the glimepiride hybrid (4b). These results represent a
significant improvement of NLRP3-inhibitory potency relative
to glyburide. The scope of variation in R2 suggests it does not
contribute significantly to NLRP3 potency, and can be altered
to interact with a second target, leading to an additional mode
of action, in this case insulin secretion.
Insulin secretion of NLRP3 inhibitors
To determine if the MCC950–sulfonylurea hybrids had retained
their insulinotropic properties we tested insulin secretion from
MIN6 cells in the presence of a single concentration (10 mm) of
test compound (Figure 3). Six hybrids (2b, 4b, 5b, 6b, 7b and
10b) demonstrated insulin secretion similar to that of glybur-
ide. The insulin-secretory hybrids, with the exception of 7b,
contained the p-b-arylcarboxamidoethyl motif common to
Gen2 sulfonylureas, which is reported to increase KATP affinity
100-fold.[21,27] While 7b lacks a p-b-arylcarboxamidoethyl motif,
the carbonyl facilitates insulin secretion, perhaps acting as a
hydrogen bond acceptor in SUR binding. The hybrids based on
Gen1 sulfonlyureas were significantly less potent, failing to
stimulate insulin secretion beyond basal glucose levels. Prior to
our study, glyburide was the only reported compound to con-
comitantly stimulate insulin secretion and inhibit NLRP3 (albeit
weakly), however our results suggest improvements to this
dual activity are certainly achievable.
Plotting insulin secretion versus NLRP3 inhibition (Figure 4),
it can be seen these MCC950–sulfonylurea hybrids fill the
chemical space between the purely NLRP3-inhibitory MCC950
and the primarily insulin-secretory glyburide. While small-mole-
cule inhibition of NLRP3 is yet to be fully explored in models
of T2D pathogenesis, a multi-targeted approach may prove
useful on combating this complex disease. Multi-targeted mol-
ecules may have pharmacokinetic and regulatory advantages
Table 1. (Continued)
Compound Structure IC50
(pIC50SD)[#]
Compound Structure IC50
(pIC50SD)[#]
Tolbutamide
(13)
>200 mm[c]
[#] The NLRP3 assay was performed using LPS-primed, ATP-stimulated BMDM. IC50 values were determined by vehicle-normalised ELISA quantification of
IL-1b. Data are expressed as the mean of n biological replicates performed in triplicate. [a] n=6, previously reported in Coll et al.[16d] [b] n=4; [c] n=3;
[d] n=2; [e] n=1.
Scheme 1. Sulfonylurea synthesis.
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over combination treatments.[28] For these reasons, compounds
possessing significant NLRP3-inhibitory and insulin-secretory
properties should undoubtedly be further explored.
Cytotoxicity
The MCC950–sulfonylurea hybrids and their parent sulfonylur-
eas were not cytotoxic up to a top concentration of 80 mm. Cy-
totoxicity was determined against a human embryonic kidney
(HEK293) cell line using the cell viability indicator resazurin. Ta-
moxifen was used as a positive control, showing a 50% cyto-
toxicity concentration (CC50)=58 mm. All data are detailed in
the Supporting Information, and represent the mean of two in-
dependent experiments performed in triplicate.
Conclusions
Screening marketed sulfonylurea drugs for NLRP3 inhibition
showed glyburide (IC50=20 mm) to be the most potent NLRP3
inhibitor, while glimepiride and gliquidone also showed
modest NLRP3 inhibition (IC50<100 mm). The corresponding
sulfonamides were similarly screened, and found to be largely
Table 2. NLRP3-inhibitory activity of MCC950–sulfonylurea hybrids.
Compd Structure IC50
(pIC50SD)[#]
Compd Structure IC50
(pIC50SD)[#]
MCC950
(1)
7.5 nm[a] 6b
167 nm[d]
(6.80.1)
2b
536 nm[b]
(6.30.1) 7b
59 nm[d]
(7.20.2)
3b
52 nm[e]
(7.30.1) 8b
15 nm[e]
(7.80.4)
4b
42 nm[c]
(7.40.2) 10b
318 nm[c]
(6.50.1)
5b
230 nm[d]
(6.60.1) 14b
57 nm[f]
(7.20.3)
[#] The NLRP3 assay was performed using LPS-primed, ATP-stimulated BMDM. IC50 values were determined by vehicle-normalised ELISA quantification of
IL-1b. Data are expressed as the mean of n biological replicates performed in triplicate. [a] n=6, previously reported in Coll et al.[16d] [b] n=5; [c] n=4;
[d] n=3; [e] n=2; [f] n=1.
Figure 3. Insulin-secretory activity of MCC950–sulfonylurea (SU) hybrids. In-
sulin secretion from MIN6 cell line in response to basal 2.8 mm glucose
(G2.8), elevated 20 mm glucose (G20) or test compounds at 10 mm concen-
tration. Insulin secretion was quantified by radioimmunoassay. Data are pre-
sented as the meanSEM of three biological replicates in triplicate;
**p<0.01 vs. G2.8, *p<0.05 vs. G2.8.
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inactive in our BMDM NLRP3 assay. Interestingly the precursor
sulfonamide of glyburide (16673-24-0) failed to inhibit NLRP3,
despite prior reports.[17] A series of MCC950–sulfonylurea hy-
brids were then synthesised and screened in a cell-based assay
against NLRP3, identifying some of the most potent NLRP3 in-
hibitors published (IC50=15–536 nm) to date. Remarkably six
NLRP3-inhibitory sulfonylureas appear to have retained their
insulin-secretory properties when tested at 10 mm. This high-
lights the ability to functionalise MCC950 with other bioactive
motifs to create small molecule chimeras. Our dual action hy-
brids fill a useful chemical space between the purely insulin se-
cretory antidiabetic sulfonylureas and highly potent NLRP3 in-
hibitors such as MCC950. These promising compounds are val-
uable tools to further understand NLRP3 activation in T2D and
may have significant therapeutic value.
Experimental Section
Mouse primary macrophage cell culture
Macrophages from C57BL/6 mice were differentiated from bone
marrow as previously described by Schroder et al.[29] The University
of Queensland Animal Ethics Committee approved all experimental
protocols involving mice. BMDM were cultured in RPMI 1640
medium (Life Technologies) supplemented with 10% heat-inactivated
fetal calf serum, 2 mm GlutaMAX (Life Technologies) and 50 UmL1
penicillin–streptomycin (Life Technologies) and 100 ngmL1 recombi-
nant human M-CSF (endotoxin free, expressed and purified by the
University of Queensland Protein Expression Facility).
NLRP3 inflammasome assay
BMDM were seeded at 1106 cellsmL1 in 96-well plates. The fol-
lowing day the overnight medium was replaced with Opti-MEM re-
duced serum medium (Life Technologies) and cells were stimulated
with 100 ngmL1 ultrapure Escherichia coli K12 LPS (Invivogen) for
3 h. Compounds were prepared as 10 mm stock solutions in 80%
DMSO/ 20% 10 mm ammonium bicarbonate and serially diluted
with Opti-MEM to allow final well concentrations of 0.001–200 mm.
Compounds or vehicle control were added to the LPS-primed cells
for 30 mins before stimulation with 2.5 mm adenosine 5’-triphos-
phate disodium salt hydrate (ATP; Sigma–Aldrich) for 1 h. IL-1b
levels in cell-free supernatants were analysed by ELISA (ReadySet-
Go! eBioscience). IC50 values were determined from ELISA quantifi-
cation of IL-1b by performing non-linear regression analysis of in-
hibitor vs. normalised response (variable slope) using Prism Soft-
ware (GraphPad).
MIN6 insulin assay
MIN6 cells (passage 29–37) were incubated for 1 h in 2.8 mm glu-
cose containing Krebs–Ringer buffer (KRB). The cells were then
stimulated for 1 h in either 2.8 mm KRB, 20 mm glucose KRB, or
2.8 mm glucose KRB plus test compound. Supernatants were col-
lected and then assayed using rat insulin radioimmunoassay kit (RI-
13K, Merck Millipore). One-way ANOVA with Tukey’s honest signifi-
cance test was performed using Prism Software.
Cytotoxicity assay
Cytotoxicity of the MCC950–sulfonylurea hybrids (2b, 3b, 4b, 5b,
6b, 7b, 8b, 10b, 14b) and their parent sulfonylureas (glyburide,
MCC950, 3, 4, 5, 6, 7, 8, 10, 14) was assessed against a Tamoxifen
(Sigma–Aldrich) positive control using a HEK293 (ATCC CRL-1573)
cell line and the cell viability indicator resazurin. HEK293 cells were
seeded at 5000 cells per well, in black, clear bottomed 384-well
tissue culture treated plates, in a volume of 20 mL DMEM medium
(GIBCO) supplemented with 10% foetal bovine serum (Scientifix)
and 50 UmL1 of penicillin and 50 mgmL1 of streptomycin
(GIBCO). Compounds, prepared in triplicate, at 80 mm to 0.625 mm
in two-fold dilutions were added to each well to a final volume of
40 mL per well and incubated for 20 h at 37 8C, 5% CO2. After the
incubation, 5 mL of 100 mm resazurin (Sigma–Aldrich) in PBS was
added to each well. The plates were then incubated for 3 h. The
fluorescence (Fl) was read at 560 nm excitation 590 nm emission
using a TECAN M1000 Pro monochromator plate reader. The data
was then analysed using Prism Software. Cell viability was calculat-
ed as an average percentage of controlSD for each set of dupli-
cate wells using the following equation: Cell viability (%)=
(FISampleFINegative/FIUntreatedFINegative)100. Using nonlinear regres-
sion analysis of log(concentration) vs. normalised cytotoxicity using
variable fitting, CC50 were calculated.
Chemistry
General : All solvents, reagents and compounds were purchased
and used without further purification unless stated otherwise. Sul-
fonamides were purchased from Sigma–Aldrich or Tokyo Chemical
Industry. 1H NMR and 13C NMR spectra were recorded using a
Bruker Avance 600 MHz spectrometer (operating at 600 MHz for
1H NMR and 151 MHz for 13C NMR) 13C and 1H chemical shifts (d),
reported in ppm, were internally referenced to tetramethylsilane.
LC–MS analysis was performed using a 0.05% (v/v) formic acid(aq)/
0.05% (v/v) formic acid in CH3CN solvent system on a Shimadzu
Prominence instrument equipped with an Agilent Eclipse XDB-
Phenyl column (3.5100 mm, 3 mm) maintained at 40 8C, SPD-
M20A diode array UV/Vis detector, ELSD-LT II evaporative light scat-
tering detector (ELSD) and LC–MS-2020 mass spectrometer. High
resolution mass spectrometry (HRMS) was performed on a Bruker
MicroTOF mass spectrometer with electrospray ionisation (ESI).
Figure 4. Dual-action sulfonylureas. [a] Insulin secretion, quantified by radio-
immunoassay, from a MIN6 cell line was measured in response to 10 mm
compound concentration. Data are presented as mean of three independent
experiments performed in triplicate, normalised to the mean secretion mea-
sured in response to 20 mm glucose concentration. [b] The NLRP3 assay was
performed using LPS-primed, ATP-stimulated BMDM. IC50 values were deter-
mined by vehicle-normalised ELISA quantification of IL-1b. Data expressed
as the mean of n biological replicates performed in triplicate as outlined in
Tables 1 and 2.
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Medium pressure liquid chromatography (MPLC) purification was
conducted on a Grace Reveleris X1 using two serial 12 g Grace C18
columns with a 10 mm NH4HCO3(aq)/CH3CN solvent system flowing
at 30 mLmin1. HPLC purification was performed on a Gilson PLC
2020 instrument using an Agilent Eclipse XDB-Phenyl column
(21.2 mm100 mm, 5 mm) with 10 mm NH4HCO3(aq)/CH3CN solvent
system flowing at 20 mLmin1.
Sulfonylurea synthesis—General method A : An isocyanate was
prepared in situ from the corresponding amine by Boc2O
(1.1 equivalent) in THF (3 mLmmol1 amine), treating with DMAP
(1.1 equivalent) and stirring for 5 min at room temperature before
adding the amine (1 equivalent) and stirring for a further 20 min.
Meanwhile a sulfonamide sodium salt was prepared in situ by dis-
solving the sulfonamide (1 equivalent) in THF (3 mLmmol1), treat-
ing with NaH (1.0 equivalent, 60% oil dispersion) and stirring
under reduced pressure until effervescence ceased (~10 min). The
sulfonamide salt and isocyanate solutions were combined and
stirred at room temperature for 15 h under N2 atmosphere, moni-
tored by LC–MS. Reaction mixtures were concentrated in vacuo,
dissolved in the minimum volume 1:1 CH3CN/N,N-dimethylforma-
mide (DMF) and purified via reversed-phase MPLC. Typically a four
minute aqueous wash followed by a 15 min 10 mm NH4HCO3(aq)/
CH3CN gradient. HPLC purification was performed where necessary
using a 15 min 0.1% formic acid(aq)/CH3CN gradient, loaded in 10%
DMF/CH3CN, whereby fractions were neutralised with the equiva-
lent volume of 10 mm NH4HCO3(aq).
5-Chloro-N-(4-(N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carba-
moyl)sulfamoyl)phenethyl)-2-methoxybenzamide (2b): 5-Chloro-
2-methoxy-N-(4-sulfamoylphenethyl)benzamide (2a) (300 mg,
0.81 mmol) was treated as per general method A to afford the
titled compound as a white solid (325 mg, 70%): 1H NMR
(600 MHz, [D6]DMSO): d=10.74 (br s, 1H), 8.27 (t, J=5.7 Hz, 1H),
8.01 (s, 1H), 7.86 (d, J=8.3 Hz, 2H), 7.65 (d, J=2.8 Hz, 1H), 7.50
(dd, J=8.9, 2.8 Hz, 1H), 7.47 (d, J=8.3 Hz, 2H), 7.13 (d, J=8.9 Hz,
1H), 6.89 (s, 1H), 3.78 (s, 3H), 3.59–3.49 (m, 2H), 2.92 (t, J=7.1 Hz,
2H), 2.75 (t, J=7.4 Hz, 4H), 2.53 (t, J=7.4 Hz, 4H), 1.89 ppm (p, J=
7.5 Hz, 4H); 13C NMR (151 MHz, [D6]DMSO): d=163.5, 155.6, 153.8,
144.4, 142.8, 136.9, 136.9, 131.4, 129.4, 129.4, 128.9, 127.1, 124.6,
124.2, 117.4, 114.0, 56.1, 40.2, 34.6, 32.3, 30.0, 24.9 ppm; HRMS (ESI-
TOF) m/z calculated for C29H29ClN3O5S [MH] 566.1522, found
566.1543; LC–MS m/z 566.2 [MH] , purity >95% (ELSD).
N-((4-Chlorophenyl)carbamoyl)-2,3-dihydro-1H-indene-5-sulfona-
mide (3): 4-Chlorobenzoic acid (1.0 g, 6.30 mmol) dissolved in tolu-
ene (10 mL) was treated with DMF (1 drop) and thionyl chloride
(9.68 mmol, 0.7 mL) then heated at reflux for 18 h. The solvent was
removed in vacuo to afford crude 4-chlorobenzoyl chloride
(1.11 mg) as a brown oil. A solution of sodium azide (550 mg,
8.46 mmol) in water (8 mL) and acetone (6 mL) was cooled to 0 8C,
and the crude acid chloride dissolved in acetone (5 mL) was added
dropwise. The toluene (216 mL) extract was concentrated in va-
cuo (without heat) to 8 mL volume and this azide solution added
dropwise into toluene at reflux under argon atmosphere. After ad-
dition the solution was heated, under argon atmosphere, until Cur-
tius rearrangement was complete (2 h). Removal of solvent in va-
cuo afforded the 1-chloro-4-isocyanatobenzene crude as a brown
oil (400 mg, 41%). 2,3-Dihydro-1H-indene-5-sulfonamide (107 mg,
0.54 mmol) dissolved in THF (1 mL) was treated with NaH in 60%
oil dispersion (24 mg, 0.63 mmol) and agitated for 10 min. Once ef-
fervescence had ceased the crude 1-chloro-4-isocyanatobenzene
dissolved in THF (0.5 mL) was added, and allowed to stir at room
temperature for 16 h. The reaction was concentrated in vacuo and
purified as per general method A to afford the titled compound as
a white solid (60 mg, 32%): 1H NMR (600 MHz, [D6]DMSO): d=
10.90 (s, 1H), 8.90 (s, 1H), 7.74 (d, J=1.4 Hz, 1H), 7.68 (dd, J=7.9,
2.0 Hz, 1H), 7.41–7.35 (m, 3H), 7.26 (d, J=9.0 Hz, 2H), 2.91 (q, J=
7.7 Hz, 4H), 2.05 ppm (p, J=7.6 Hz, 2H); 13C NMR (151 MHz,
DMSO): d=151.2, 148.9, 144.2, 139.3, 138.0, 128.4, 125.7, 125.5,
124.1, 122.9, 119.9, 32.2, 32.0, 24.9 ppm; HRMS (ESI-TOF) m/z calcu-
lated for C16H14ClN2O3S [MH] 349.0419, found, 349.0418; LC–MS
m/z 351.0 [M+H]+ , purity >95% (ELSD).
N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-2,3-dihydro-
1H-indene-5-sulfonamide (3b): 2,3-Dihydro-1H-indene-5-sulfona-
mide (3a) (200 mg, 1.01 mmol) was treated as per general method
A to afford the titled compound as a white solid (48 mg, 12%):
1H NMR (600 MHz, [D6]DMSO): d=10.68 (br s, 1H), 8.02 (s, 1H), 7.75
(d, J=1.6 Hz, 1H), 7.69 (dd, J=7.9, 1.6 Hz, 1H), 7.41 (d, J=7.9 Hz,
1H), 6.91 (s, 1H), 2.92 (m, 4H), 2.77 (t, J=7.4 Hz, 4H), 2.53 (t, J=
7.4 Hz, 4H), 2.05 (p, J=7.5 Hz, 2H), 1.91 ppm (p, J=7.4 Hz, 4H);
13C NMR (151 MHz, [D6]DMSO): d=149.5, 149.4, 144.5, 142.9, 138.2,
137.0, 128.7, 125.3, 124.4, 122.8, 117.7, 32.3, 32.2, 32.0, 30.0, 25.0,
24.9 ppm; HRMS (ESI-TOF) m/z calculated for C22H23N2O3S [MH]
395.1435, found 395.1430; LC–MS m/z 397.1 [M+H]+ , purity
>95% (ELSD).
3-Ethyl-N-(4-(N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carba-
moyl)sulfamoyl)phenethyl)-4-methyl-2-oxo-2,5-dihydro-1H-pyr-
role-1-carboxamide (4b): 3-Ethyl-4-methyl-2-oxo-N-(4-sulfamoyl-
phenethyl)-2,5-dihydro-1H-pyrrole-1-carboxamide (4a) (100 mg,
0.29 mmol) was treated as per general method A to afford the
titled compound as a white solid (78 mg, 50%): 1H NMR (600 MHz,
[D6]DMSO): d=10.73 (br s, 1H), 8.38 (t, J=5.8 Hz, 1H), 8.04 (s, 1H),
7.84 (d, J=8.4 Hz, 2H), 7.45 (d, J=8.4 Hz, 2H), 6.90 (s, 1H), 4.16 (s,
2H), 3.52–3.45 (m, 2H), 2.89 (t, J=7.2 Hz, 2H), 2.75 (t, J=7.5 Hz,
4H), 2.52 (d, J=7.4 Hz, 4H), 2.18 (q, J=7.5 Hz, 2H), 2.00 (s, 3H),
1.90 (p, J=7.5 Hz, 4H), 0.97 ppm (t, J=7.5 Hz, 3H); 13C NMR
(151 MHz, [D6]DMSO): d=171.8, 152.1, 151.7, 149.8, 144.7, 143.0,
138.6, 137.2, 131.9, 129.1, 129.0, 127.4, 117.8, 51.9, 40.2, 35.3, 32.5,
30.1, 25.0, 16.0, 12.9, 12.8 ppm; HRMS (ESI-TOF) m/z calculated for
C29H33N4O5S [MH] 549.2177; found 549.2169. LCMS: m/z 573.47
[M+Na]+ , purity >95% (ELSD).
4-(2-(7-Methoxy-4,4-dimethyl-1,3-dioxo-3,4-dihydroisoquinolin-
2(1H)-yl)ethyl)benzenesulfonamide (5a): N-(Cyclohexylcarbamo-
yl)-4-(2-(7-methoxy-4,4-dimethyl-1,3-dioxo-3,4-dihydroisoquinolin-
2(1H)-yl)ethyl)benzenesulfonamide (5) (504 mg, 0.96 mmol) dis-
solved in pyridine (8 mL) was treated with phthalic anhydride
(143 mg, 0.97 mmol) and DMAP (11.8 mg, 0.097 mmol), then
heated at reflux for 5 h under N2 atmosphere. The reaction mixture
was purified by MPLC, affording the titled compound as an amor-
phous white solid (291 mg, 77%): 1H NMR (600 MHz, [D6]DMSO):
d=7.72 (d, J=8.5 Hz, 2H), 7.61 (d, J=8.8 Hz, 1H), 7.53 (d, J=
2.9 Hz, 1H), 7.40 (d, J=8.5 Hz, 2H), 7.33–7.26 (m, 3H), 4.13 (t, J=
7.4 Hz, 2H), 3.84 (s, 3H), 2.93 (t, J=7.4 Hz, 2H), 1.45 (s, 6H);
13C NMR (151 MHz, [D6]DMSO): d=176.3, 163.1, 158.0, 142.6, 142.2,
137.2, 129.1, 127.4, 125.6, 124.1, 121.5, 110.5, 55.3, 42.3, 40.4, 32.9,
28.8; HRMS (ESI-TOF) m/z calculated for C20H21N2O5S [MH]
401.1177, found 401.1174; LC–MS m/z : 403.1 [M+H]+ , purity
>95% (ELSD).
N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-4-(2-(7-me-
thoxy-4,4-dimethyl-1,3-dioxo-3,4-dihydroisoquinolin-2(1H)-yl)-
ethyl)benzenesulfonamide (5b): 4-(2-(7-Methoxy-4,4-dimethyl-1,3-
dioxo-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)benzene sulfonamide
(5a) (111 mg, 0.276 mmol) was treated as per general method A to
afford the titled compound as a white solid (85 mg, 52%): 1H NMR
(600 MHz, [D6]DMSO): d=10.72 (br s, 1H), 7.91 (s, 1H), 7.80 (d, J=
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8.0 Hz, 2H), 7.58 (d, J=8.7 Hz, 1H), 7.53 (d, J=2.9 Hz, 1H), 7.39 (d,
J=8.0 Hz, 2H), 7.29 (dd, J=8.7, 2.9 Hz, 1H), 6.88 (s, 1H), 4.13 (t, J=
7.5 Hz, 2H), 3.83 (s, 3H), 2.93 (t, J=7.4 Hz, 2H), 2.76 (t, J=7.4 Hz,
4H), 2.55 (t, J=7.4 Hz, 4H), 1.90 (p, J=7.4 Hz, 4H), 1.42 ppm (s,
6H); 13C NMR (151 MHz, DMSO): d=176.3, 163.1, 158.0, 150.1,
143.5, 142.8, 137.1, 136.9, 129.1, 129.0, 127.4, 127.1, 125.6, 124.1,
121.4, 117.4, 110.4, 55.3, 42.3, 40.3, 33.0, 32.3, 30.0, 28.8, 24.9 ppm;
HRMS (ESI-TOF) m/z calculated for C33H34N3O6S [MH] 600.2174,
found 600.2183; LC–MS m/z 602.4 [M+H]+ , purity >95% (ELSD).
5-Methyl-N-(4-sulfamoylphenethyl)isoxazole-3-carboxamide
(6a): 5-Methylisoxazole-3-carboxylic acid (150 mg, 1.18 mmol) dis-
solved in toluene (2 mL) was treated with DMF (1 drop) and thionyl
chloride (1.42 mmol, 103 mL) then heated at reflux for 5 h. The sol-
vent was removed in vacuo to afford crude 5-methylisoxazole-3-
carbonyl chloride (155 mg, 1.06 mmol) as a brown oil. The crude
acid chloride was dissolved in THF (4 mL), treated with Et3N
(155 mL, 1.06 mmol) and stirred for 5 min, before adding 4-(2-ami-
noethyl)benzenesulfonamide (220 mg, 1.10 mmol). The reaction
was stirred at room temperature for 15 h under N2 atmosphere.
The reaction was concentrated in vacuo and purified by MPLC, af-
fording the titled compound as an amorphous white solid
(205 mg, 62%): 1H NMR (600 MHz, [D6]DMSO): d=8.79 (t, J=5.8 Hz,
1H), 7.74 (d, J=8.3 Hz, 2H), 7.41 (d, J=8.3 Hz, 2H), 7.30 (s, 2H),
6.50 (q, J=0.8 Hz, 1H), 3.49 (m, 2H), 2.91 (t, J=7.2 Hz, 2H),
2.45 ppm (d, J=0.8 Hz, 3H); 13C NMR (151 MHz, [D6]DMSO): d=
171.0, 158.8, 158.5, 143.3, 142.0, 129.0, 125.6, 101.1, 39.8, 34.3,
11.7 ppm; HRMS (ESI-TOF) m/z calculated for C13H14N3O4S [MH]
308.0711, found 308.0708; LC–MS m/z 308.0 [M+H]+ , purity
>99% (ELSD).
N-(4-(N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)sulfa-
moyl)phenethyl)-5-methylisoxazole-3-carboxamide (6b): 5-
Methyl-N-(4-sulfamoylphenethyl) isoxazole-3-carboxamide (6a)
(14 mg, 0.044 mmol) was treated as per general method A. Further
MPLC purification used 0.05% formic acid(aq)/ 0.05% formic acid in
CH3CN gradient elution. Lyophilisation of the appropriate fractions
afforded the titled compound as a white solid (14 mg, 62%):
1H NMR (600 MHz, [D6]DMSO): d=10.73 (br s, 1H), 8.81 (t, J=
5.8 Hz, 1H) 8.09 (s, 1H), 7.86 (d, J=8.2 Hz, 2H), 7.47 (d, J=8.2 Hz,
2H), 6.92 (s, 1H), 6.49 (s, 1H), 3.49 (m, 2H), 2.93 (t, J=7.2 Hz, 2H),
2.76 (t, J=7.2 Hz, 4H), 2.52 (m, 4H), 2.44 (s, 3H), 1.90 ppm (p, J=
7.2 Hz, 4H); 13C NMR (151 MHz, [D6]DMSO): d=171.0, 158.7, 158.5,
148.9, 145.0, 142.9, 137.8, 137.1, 129.1, 128.5, 127.2, 117.9, 101.1,
39.9, 34.4, 32.3, 29.9, 24.9, 11.7 ppm; HRMS (ESI-TOF) m/z calculat-
ed for C26H27N4O5S [MH] 507.1708, found 507.1709; LC–MS m/z
509.4 [M+H]+ , purity >95% (ELSD).
4-Acetyl-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)ben-
zenesulfonamide (7b): 4-Acetylbenzenesulfonamide (7a) (100 mg,
0.50 mmol) was treated as per general method A to afford the
titled compound as a white solid (31 mg, 16%): 1H NMR (600 MHz,
[D6]DMSO): d=11.03 (br s, 1H), 8.08 (d, J=8.5 Hz, 2H), 7.99 (d, J=
8.5 Hz, 2H), 7.07 (br s, 1H), 6.87 (s, 1H), 2.75 (t, J=7.4 Hz, 4H), 2.62
(s, 3H), 2.56 (t, J=7.4 Hz, 4H), 1.90 ppm (p, J=7.4 Hz, 4H);
13C NMR (151 MHz, [D6]DMSO): d=197.3, 151.8, 142.6, 138.9, 136.9,
129.7, 128.2, 127.2, 117.1, 32.4, 30.1, 26.9, 24.9 ppm; HRMS (ESI-
TOF) m/z calculated for C21H21N2O4S [MH] 397.1228, found
397.1225; LC–MS m/z 399.1 [M+H]+ , purity >95% (ELSD).
4-Amino-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-
benzenesulfonamide (8b): N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-
yl)carbamoyl)-4-nitrobenzenesulfonamide (14b) (40.0 mg,
0.100 mmol) was dissolved in EtOAc/DMF (4:1, 2.5 mL) and stirred
at room temperature for 1 h under hydrogen atmosphere with
10% palladium on carbon (5 mol%) catalyst. Filtration through
Celite and purification by MPLC afforded the titled compound as a
white solid (16 mg, 43%): 1H NMR (600 MHz, [D6]DMSO): d=10.08
(br s, 1H), 7.95 (s, 1H), 7.54 (d, J=8.8 Hz, 2H), 6.91 (s, 1H), 6.59 (d,
J=8.8 Hz, 2H), 6.05 (s, 2H), 2.77 (t, J=7.5 Hz, 4H), 2.55 (t, J=
7.5 Hz, 4H), 1.92 ppm (p, J=7.5 Hz, 4H); 13C NMR (151 MHz,
[D6]DMSO): d=153.0, 149.4, 142.9, 136.8, 129.2, 128.9, 124.9, 117.6,
112.1, 32.3, 30.0, 24.9 ppm; HRMS (ESI-TOF) m/z calculated for
C19H20N3O3S [MH] 370.1231, found 370.1225; LC–MS m/z 372.1
[M+H]+ , purity >95% (ELSD).
5-Methyl-N-(4-sulfamoylphenethyl)pyrazine-2-carboxamide
(10a): N-(4-(N-(Cyclohexylcarbamoyl)sulfamoyl)phenethyl)-5-meth-
ylpyrazine-2-carboxamide (11) (250 mg, 0.56 mmol) dissolved in
pyridine (8 mL) was treated with phthalic anhydride (83 mg,
0.56 mmol) and DMAP (10 mg, 0.082 mmol), then heated at reflux
for 5 h under N2 atmosphere. The reaction mixture was purified by
MPLC affording the titled compound as an amorphous white solid
(113 mg, 63%): 1H NMR (600 MHz, [D6]DMSO): d=9.03 (d, J=
1.4 Hz, 1H), 8.96 (t, J=6.0 Hz, 1H), 8.61 (m, 1H), 7.73 (d, J=8.4 Hz,
2H), 7.42 (d, J=8.4 Hz, 2H), 7.30 (s, 2H), 3.57 (dt, J=7.3, 6.0 Hz,
2H), 2.95 (t, J=7.3 Hz, 2H), 2.58 ppm (s, 3H); 13C NMR (151 MHz,
[D6]DMSO): d=162.8, 156.7, 143.4, 142.7, 142.3, 141.9, 141.9, 129.0,
125.6, 39.9, 34.6, 21.2 ppm; HRMS (ESI-TOF) m/z calculated for
C14H17N4O3S [M+H]
+ 321.1016, found 321.1029; LC–MS m/z 321.0
[M+H]+ , purity >95% (ELSD).
N-(4-(N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)sulfa-
moyl)phenethyl)-5-methylpyrazine-2-carboxamide (10b): 5-
Methyl-N-(4-sulfamoylphenethyl)pyrazine-2-carboxamide (10a)
(100 mg, 0.312 mmol) was treated as per general method A to
afford a crude white solid (72 mg). Further HPLC purification using
a 0.1% formic acid(aq)/ CH3CN mobile phase and 10% DMSO/
CH3CN loading solvent, whereby fractions were neutralised with
10 mm NH4HCO3(aq), yielded a white solid (14 mg, 9%):
1H NMR
(600 MHz, [D6]DMSO): d=9.03 (d, J=1.0 Hz, 1H), 8.93 (t, J=5.9 Hz,
1H), 8.59 (d, J=1.0 Hz, 1H), 7.77 (d, J=8.1 Hz, 2H), 7.36 (d, J=
8.1 Hz, 2H), 6.84 (s, 1H), 6.53 (br s, 1H), 3.58–3.51 (m, 2H), 2.93 (t,
J=7.3 Hz, 2H), 2.74 (t, J=7.3 Hz, 4H), 2.58 (s, 3H), 2.55 (t, J=
7.3 Hz, 4H), 1.88 ppm (p, J=7.4 Hz, 4H); 13C NMR (151 MHz,
[D6]DMSO): d=162.8, 156.7, 147.7, 143.0, 142.7, 142.5, 142.3, 141.9,
141.6, 136.7, 128.4, 126.8, 125.6, 116.7, 39.9, 34.6, 32.4, 30.1, 24.9,
21.2 ppm; HRMS (ESI-TOF) m/z calculated for C27H30N5O4S [M+H]
+
520.2020, found 520.2030; LC–MS m/z 520.1 [M+H]+ , purity
>95% (ELSD).
N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-4-nitroben-
zenesulfonamide (14b): 4-Nitrobenzenesulfonyl chloride (300 mg,
1.35 mmol) dissolved in acetone (1 mL) was added dropwise to
NH4HCO3(aq) (450 mg, 5.42 mmol, 4 mL) and stirred at room temper-
ature for 2 h. The reaction mixture was then acidified with 1m HCl
(to pH2) and extracted with EtOAc (310 mL). The organic
layers were combined, washed with brine (20 mL), water (20 mL)
and dried (MgSO4). Solvent was removed in vacuo to afford 4-nitro-
benzenesulfonamide as a pale orange solid (157 mg, 57%): 1H NMR
(600 MHz, [D6]DMSO): d=8.42 (d, J=9.0 Hz, 2H), 8.06 (d, J=9.0 Hz,
2H, 7.74 ppm (s, 2H); HRMS (ESI-TOF) m/z calculated for C6H5N2O4S
[MH] 200.9976, found 200.9984; LC–MS m/z 200.9 [MH] ,
purity >99% (ELSD). 4-Nitrobenzenesulfonamide (124 mg,
0.613 mmol) was treated as per general method A to afford the
titled compound as a pale yellow solid (148 mg, 60%): 1H NMR
(600 MHz, [D6]DMSO): d=10.00 (br s, 1H), 8.21 (d, J=9.0 Hz, 2H),
7.97 (d, J=9.0 Hz, 2H), 7.45 (s, 1H), 6.75 (s, 1H), 2.73 (t, J=7.4 Hz,
4H), 2.61 (t, J=7.4 Hz, 4H), 1.87 ppm (p, J=7.4 Hz, 4H); 13C NMR
(151 MHz, [D6]DMSO): d=158.0, 153.8, 147.4, 141.9, 136.4, 132.5,
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127.8, 122.8, 115.4, 32.5, 30.4, 25.0 ppm; HRMS (ESI-TOF) m/z calcu-
lated for C19H18N3O5S [MH] 400.0973, found 400.0979; LC–MS m/
z 402.1 [M+H]+ , purity >95% (ELSD).
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